PCSK9 inhibitors are recommended in primary prophylactic treatment for cardiovascular disease when the lipid target in accordance with cardiovascular risk is not achieved during treatment with statins at the highest tolerated dose or in secondary prevention to a cardiovascular event [61]. The gene discussed is PCSK9; the disease is cardiovascular disorder.